Upstream Bio, Inc. (NASDAQ:UPB) Receives Consensus Recommendation of “Hold” from Brokerages

Shares of Upstream Bio, Inc. (NASDAQ:UPB) have been assigned a consensus recommendation of “Hold” from the five research firms that are covering the firm, Marketbeat Ratings reports. One research analyst has rated the stock with a sell recommendation, one has issued a hold recommendation and three have issued a buy recommendation on the company. The average 12-month price objective among analysts that have issued ratings on the stock in the last year is $38.75.

A number of brokerages recently weighed in on UPB. Weiss Ratings downgraded shares of Upstream Bio from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Wednesday, May 6th. Evercore downgraded shares of Upstream Bio from an “outperform” rating to an “in-line” rating and set a $15.00 price objective on the stock. in a research report on Friday, March 27th. Mizuho lowered their price objective on shares of Upstream Bio from $51.00 to $50.00 and set an “outperform” rating on the stock in a research report on Thursday. Finally, Wall Street Zen downgraded shares of Upstream Bio from a “hold” rating to a “sell” rating in a research report on Saturday, March 28th.

Institutional Inflows and Outflows

Several institutional investors have recently added to or reduced their stakes in UPB. GF Fund Management CO. LTD. bought a new position in Upstream Bio in the fourth quarter worth approximately $29,000. Torren Management LLC bought a new position in Upstream Bio in the fourth quarter worth approximately $30,000. BNP Paribas Financial Markets raised its position in Upstream Bio by 229.8% in the second quarter. BNP Paribas Financial Markets now owns 3,097 shares of the company’s stock worth $34,000 after acquiring an additional 2,158 shares during the period. Legal & General Group Plc raised its position in Upstream Bio by 83.0% in the second quarter. Legal & General Group Plc now owns 3,174 shares of the company’s stock worth $35,000 after acquiring an additional 1,440 shares during the period. Finally, Empowered Funds LLC bought a new position in Upstream Bio in the fourth quarter worth approximately $45,000.

Upstream Bio Stock Up 3.4%

Shares of Upstream Bio stock opened at $9.09 on Friday. The company has a market cap of $494.68 million, a price-to-earnings ratio of -3.12 and a beta of 1.28. The company’s 50 day moving average is $9.26 and its 200 day moving average is $19.20. Upstream Bio has a twelve month low of $7.25 and a twelve month high of $33.68.

Upstream Bio (NASDAQ:UPB) last issued its quarterly earnings data on Wednesday, May 13th. The company reported ($0.75) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.73) by ($0.02). The company had revenue of $1.03 million for the quarter, compared to the consensus estimate of $1.03 million. Upstream Bio had a negative net margin of 4,718.96% and a negative return on equity of 43.82%. Sell-side analysts expect that Upstream Bio will post -2.99 EPS for the current fiscal year.

Upstream Bio Company Profile

Upstream Bio, Inc is a clinical-stage biotechnology company focused on the development of next-generation prophylactic vaccines and immuno-oncology therapies. Leveraging a proprietary viral vector platform, the company aims to deliver optimized antigen payloads that stimulate robust and durable immune responses against both infectious diseases and cancer targets. Upstream Bio’s approach emphasizes safety, manufacturability and potential for rapid scale-up to address emerging public health challenges.

The company’s research and development pipeline includes multiple viral vector-based candidates in early clinical and preclinical stages.